<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077697</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0047</org_study_id>
    <nct_id>NCT04077697</nct_id>
  </id_info>
  <brief_title>Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.</brief_title>
  <acronym>ITBA</acronym>
  <official_title>Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Lens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive tracheobronchial aspergillosis (ITBA) is an uncommon, but severe clinical form of
      Invasive Pulmonary Aspergillosis (IPA) in which the fungal infection is entirely or
      predominantly confined to the tracheobronchial tree. In view of the limited data concerning
      critically ill patients admitted to the intensive care unit (ICU) with severe influenza
      associated with ITBA, the investigators decided to evaluate the differences between the
      clinical presentations of two invasive infections: ITBA and IPA without tracheobronchial
      involvement (No ITBA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Invasive pulmonary aspergillosis (IPA) is a well-known complication in severely
      immunocompromised hosts patients. Recent evidence has identified others populations at risk
      for IPA, including those with chronic obstructive pulmonary disease (COPD) and advanced
      cirrhosis patients in intensive care units (ICUs). Moreover, Recently influenza has been
      identified as a new independent risk factor for IPA and IPA was described as an early
      complication of influenza. IPA groups different clinical presentations: the classical
      angio-invasive, the broncho-invasive form and the invasive tracheobronchitis aspergillosis
      form (ITBA).

      ITBA is an infrequent clinical form of IPA with often a fatal outcome, in which Aspergillus
      infection involves entirely or predominantly the tracheobronchial tree. Early diagnosis of
      ITBA is based on bronchoscopy examination. Severe influenza is a life-threatening condition
      where IPA has been repeatedly reported. Little is known on severe influenza infection
      complicated with IPA and still less with ITBA. Current data on ITBA in critically ill
      patients hospitalized for severe influenza infection has only been described in single case
      reports. Because ITBA has been associated with a poorer prognostic than other forms of IPA,
      this retrospective study aimed to analyze diagnostic and prognostic differences between ITBA
      and IPA without tracheobronchial lesions, in critically ill patients with influenza infection
      hospitalized in ICU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">July 16, 2019</completion_date>
  <primary_completion_date type="Actual">July 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of management of ITBA diagnosis criteria</measure>
    <time_frame>from day 0 to two weeks after the start of the study</time_frame>
    <description>Evolution of the diagnosis criteria of the ITBA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of management of ITBA prognosis</measure>
    <time_frame>from day 0 to two weeks after the start of the study</time_frame>
    <description>Evolution of ITBA prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mortality rate between ITBA group and IPA group</measure>
    <time_frame>from day 0 to two weeks after the start of the study</time_frame>
    <description>ITBA group is : invasive tracheobronchitis aspergillosis form. IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <condition>Morality</condition>
  <arm_group>
    <arm_group_label>ITBA group</arm_group_label>
    <description>ITBA group is : invasive tracheobronchitis aspergillosis form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPA without tracheobronchial involvement</arm_group_label>
    <description>IPA group is : invasive pulmonary aspergillosis without tracheobronchial involvement</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RT-PCR for influenza</intervention_name>
    <description>influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.</description>
    <arm_group_label>IPA without tracheobronchial involvement</arm_group_label>
    <arm_group_label>ITBA group</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients eligible for inclusion were patients with a diagnosis of influenza confirmed by a
        positive influenza real time polymerase chain reaction (RT-PCR) from nasopharyngeal swab or
        bronchoalveolar lavage (BAL) fluid, with a concomitant diagnosis of proven or
        probable/putative IPA and the performing of a bronchoscopy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all ICU (Intensive care unit) patients

          -  patients aged from 18 years and more

          -  All patients hospitalized in ICU with a positive influenza RT-PCR extracted from the
             registry of the local virology department

          -  patients with a diagnosis of influenza confirmed by a positive influenza real time
             polymerase chain reaction (RT-PCR) from nasopharyngeal swab or bronchoalveolar lavage
             (BAL) fluid, with a concomitant diagnosis of proven or probable/putative IPA and the
             performing of a bronchoscopy

        Exclusion Criteria:

          -  minor or adult with guardianship

          -  absence of hospitalization in intensive care

          -  influenza infection not confirmed by PCR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Zogheib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Taieb Chouaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Dupont, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien Maizel, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rémy Nyga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivona Milic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saad NSEIR, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boualem SENDID, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcom LEMYSE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>invasive pulmonary aspergillosis</keyword>
  <keyword>Invasive TracheoBronchial Aspergillosis</keyword>
  <keyword>galactomannan</keyword>
  <keyword>1,3-β-D-Glucan</keyword>
  <keyword>influenza</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

